NATURAL SITE PREFERENCE IN MAMMARY CANCER BIOLOGY

乳腺癌生物学中的自然位点偏好

基本信息

项目摘要

I have found that mouse mammary tumors demonstrate a remarkable preference for growth in their natural anatomic site, the mammary fatpad. Furthermore, mouse mammary tumors were found to metastasize more readily from the mammary fatpad than from subcutaneous sites. I have shown that immunological mechanisms do not adequately explain these observed site effects on tumor growth and metastasis and have focused on intraepithelial and stromal-epithelial cellular interactions as alternative mechanisms. Interactive homeostatic mechanisms occur between cells from the time of blastlal formation. These regulatory processes are usually able to maintain tissue integrity throughout life and can be regarded as mechanisms of "non-immune surveillance" against neoplasia. In the mouse, normal mammary gland tissue interactions can be demonstrated as early as in the 11\day (in utero) fetal mammary bud, in the virgin female, during pregnancy/lactation related glandular remodeling, between mammary epithelium and preneoplastic mammary tissues, and, as I have shown, between normal mammary gland tissues and malignant mammary tissues. Manipulation of tissue interactions could lead to new therapeutic strategies against cancer growth and progression. I have developed mammary tumor lines with drug resistance markers and have utilized these to study metabolic cooperation between mammary tissues. I have adapted the three-dimensional culture system in collagen gel to study tissue interactions in vitro, and I have begun to utilize embryonic tissues as a defined source of functional mammary mesechyme to study epithelial-mesenchymal interactions with mammary tumor cells. These new tools will aid my continuing investigations of mammary tumors growing in their natural anatomic site to determine both the mechanisms of site preference and their consequences. The study of mechanism will continue to focus on cellular interactions within the mammary gland fatpad. The studies of the consequences will focus on the affect of mammary gland tissue interactions on neoplastic progression. My experimental approaches are based on the principles that cell shape, tissue architecture, the extracellular matrix, and both stromal-epithelial and intraepithelial interactions may all play significant roles in the normal growth and development of the mammary gland.
我发现小鼠乳腺肿瘤表现出明显的 生长在它们的自然解剖部位,乳房脂肪垫。 此外,发现小鼠乳腺肿瘤更容易转移 而不是皮下组织。 我已经证明, 免疫学机制不能充分解释这些观察到位点 对肿瘤生长和转移的影响,并集中在上皮内 和基质-上皮细胞相互作用作为替代机制。 细胞之间的相互作用的自我平衡机制发生在 胚囊形成 这些监管程序通常能够 在整个生命周期中保持组织完整性, 对肿瘤的“非免疫监视”。 在小鼠中,正常 乳腺组织的相互作用早在 11天(子宫内)胎儿乳芽,处女,期间 妊娠/哺乳相关的腺体重塑,乳房之间 上皮和癌前乳腺组织,以及,如我所示, 正常乳腺组织和恶性乳腺组织。 操纵 组织相互作用的研究可能会导致新的治疗策略, 癌症的生长和进展。 我已经发展出乳腺肿瘤线, 耐药标记,并利用这些来研究代谢 乳腺组织之间的合作。 我已经改编了三维的 培养系统中的胶原蛋白凝胶,研究组织的相互作用,在体外,我 已经开始利用胚胎组织作为一种确定的功能来源, 乳腺间质研究上皮-间充质相互作用与乳腺癌 肿瘤细胞 这些新工具将有助于我继续调查 乳腺肿瘤在其自然解剖部位生长,以确定 地点偏好的机制及其后果。 研究 机制将继续关注细胞内的相互作用 乳腺脂肪垫 对后果的研究将集中在 乳腺组织相互作用对肿瘤进展的影响。 我 实验方法基于细胞形状、组织 结构,细胞外基质,以及基质-上皮和 上皮内相互作用可能在正常的 乳腺的生长和发育。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRED Raymond MILLER其他文献

FRED Raymond MILLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRED Raymond MILLER', 18)}}的其他基金

Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
  • 批准号:
    6470342
  • 财政年份:
    2002
  • 资助金额:
    $ 13.28万
  • 项目类别:
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
  • 批准号:
    6849197
  • 财政年份:
    2002
  • 资助金额:
    $ 13.28万
  • 项目类别:
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
  • 批准号:
    6698074
  • 财政年份:
    2002
  • 资助金额:
    $ 13.28万
  • 项目类别:
MCF10DCIS.com as a preclinical chemopreventive screen
MCF10DCIS.com 作为临床前化学预防筛查
  • 批准号:
    6439397
  • 财政年份:
    2002
  • 资助金额:
    $ 13.28万
  • 项目类别:
MCF10DCIS.com as a preclinical chemopreventive screen
MCF10DCIS.com 作为临床前化学预防筛查
  • 批准号:
    6620013
  • 财政年份:
    2002
  • 资助金额:
    $ 13.28万
  • 项目类别:
Proteomics of Progression in MCF10 Xenograft Model
MCF10 异种移植模型进展的蛋白质组学
  • 批准号:
    6623819
  • 财政年份:
    2002
  • 资助金额:
    $ 13.28万
  • 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
  • 批准号:
    2101948
  • 财政年份:
    1993
  • 资助金额:
    $ 13.28万
  • 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
  • 批准号:
    2101949
  • 财政年份:
    1993
  • 资助金额:
    $ 13.28万
  • 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
  • 批准号:
    2101950
  • 财政年份:
    1993
  • 资助金额:
    $ 13.28万
  • 项目类别:
LYMPHOKINE-TISSUE INTERACTIONS IN PRENEOPLASIA
肿瘤前期的淋巴因子与组织的相互作用
  • 批准号:
    3204700
  • 财政年份:
    1993
  • 资助金额:
    $ 13.28万
  • 项目类别:

相似海外基金

Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
  • 批准号:
    nhmrc : 950215
  • 财政年份:
    1995
  • 资助金额:
    $ 13.28万
  • 项目类别:
    NHMRC Project Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了